Saito et al., 2003 - Google Patents
Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular …Saito et al., 2003
View PDF- Document ID
- 125081907697709648
- Author
- Saito K
- Takeda K
- Imanaka-Yoshida K
- Imai H
- Sekine T
- Kamikura Y
- Publication year
- Publication venue
- Annals of nuclear medicine
External Links
Snippet
We investigated myocardial fatty acid metabolism in taxan-induced myocardial damage in patients with advanced lung cancer. Patients and Methods: Twenty-five patients with non- small-cell lung cancer were treated with taxan combined with carboplatin intravenously for …
- 230000002107 myocardial 0 title abstract description 55
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11071770B2 (en) | Methods for detecting cardiac damage | |
Mitani et al. | Doxorubicin cardiotoxicity: prevention of congestive heart failure with serial cardiac function monitoring with equilibrium radionuclide angiocardiography in the current era | |
Maes et al. | Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings. | |
Avril et al. | Monitoring response to treatment in patients utilizing PET | |
Cochet et al. | Baseline diastolic dysfunction as a predictive factor of trastuzumab-mediated cardiotoxicity after adjuvant anthracycline therapy in breast cancer | |
Saito et al. | Assessment of fatty acid metabolism in taxan-induced myocardial damage with iodine-123 BMIPP SPECT: comparative study with myocardial perfusion, left ventricular function, and histopathological findings | |
Ruggiero et al. | Anthracycline cardiotoxicity in childhood | |
Wachters et al. | Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment | |
Kremer et al. | Indium-111–Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children | |
Wakabayashi et al. | Assessment of Doxorubicin Cardiac Toxicity Using Gated 99mTc-Hexakis-2-Methoxyisobutylisonitrile Myocardial Single Photon Emission Computed Tomography–Wall Thickening and Motion Abnormalities Can Be an Early Sign of Cardiac Involvement– | |
Goncalves et al. | High-dose alkylating agents with autologous hematopoietic stem cell support and trastuzumab in ERBB2 overexpressing metastatic breast cancer: a feasibility study | |
Fujino et al. | Recovery of BMIPP uptake and regional wall motion in insulin resistant patients following angioplasty for acute myocardial infarction | |
De Maria et al. | Morphological bases for thallium-201 uptake in cardiac imaging and correlates with myocardial blood flow distribution | |
Li et al. | Immune myocarditis induced by sintilimab therapy: A case report | |
Kucukosmanoglu et al. | Correlation of [18F] FDG PET activity with expressions of Ki-67 in non-small-cell lung cancer | |
Gemma et al. | Phase I/II study of paclitaxel+ carboplatin for refractory or recurrent non-small cell lung cancer | |
AU2014202390B2 (en) | Methods for detecting cardiac damage | |
Dompieri et al. | Nuclear Medicine Tools for Cardiac Damage Diagnosis in Oncology | |
堀優作 | Preclinical evaluation using in vivo radiological imaging in mouse cancer models | |
Costedoat-Chalumeau et al. | CNS involvement and treatment with interferon-are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients | |
Cowley et al. | Functional diagnostic imaging in the assessment of myocardial viability | |
Teresińska et al. | Assessment of myocardial perfusion and viability with stress Tc-99m-MIBI SPECT before surgical revascularisation. Correlation with postoperative perfusion improvement | |
Viale et al. | Cardiovascular toxicity associated with cancer treatment [corrected][published erratum appears in CLIN J ONCOL NURS 2008 Oct; 12 (5): 705]. | |
Catalin Loghin et al. | Articles in PresS. Am J Physiol Heart Circ Physiol (September 1, 2006). doi: 10.1152/ajpheart. 00818.2006 |